AEZS Transformation zum Big Player
Da würde die Zulassung (und dann auch Einnahmen) sowieso schneller kommen als bei Zop.
gezockt nach der "Separation Time"?
Pursuant to the terms of the Rights Plan, one right was issued in respect of each Common Share outstanding at 5:01 p.m. on March 29, 2016 (the "Record Time"). In addition, we will issue one right for each additional Common Share issued after the Record Time, and prior to the earlier of the "Separation Time" (as defined in the Rights Plan) and the Expiration Time (as defined in the Rights Plan). The rights have an initial exercise price equal to the Market Price (as defined in the Rights Plan) of the Common Shares as determined at the Separation Time, multiplied by five, subject to certain anti-dilution adjustments (the "Exercise Price"), and they are not exercisable until the Separation Time. Upon the occurrence of a Flip-in Event (as defined in the Rights Plan), each right will entitle the holder thereof, other than an Acquiring Person (as defined in the Rights Plan) or any other person whose rights are or become void pursuant to the provisions of the Rights Plan, to purchase from us, effective at the close of business on the eighth trading day after the Stock Acquisition Date (as defined below), upon payment to us of the Exercise Price, Common Shares having an aggregate Market Price equal to twice the Exercise Price on the date of consummation or occurrence of such Flip-in Event, subject to certain anti-dilution adjustments.
http://secfilings.nasdaq.com/...INC.&FormType=F-3/A&View=html
Könnte man so auslegen .
Die letzten Hunde bekommen fünf Frolix ! LOL
aber Glück gehabt das er rechtzeitig gekauft hat!
Aeterna Zentaris AnnouncesAdditional Market Purchases of Common Shares by Executive Management
Monday, January 25, 2016 12:00 pm EST
http://ir.aezsinc.com/press-release/...chases-common-shares-executive
The ZoptEC study was designed to permit the final analysis of the data from the study to occur following the deaths of 384 patients. On January 30, 2017, we announced the occurrence of the 384th death, representing the clinical endpoint of the study. We expect clinical database lock and reporting of top-line results to occur by early May 2017. If the results of the ZoptEC study warrant doing so, we expect to file an NDA in the United States for Zoptrex™ in the third quarter of 2017. We are now moving forward with our planning to commercialize Zoptrex™, looking toward commercial launch of the product in 2018, assuming positive Phase 3 results and that the NDA is granted.
Such wenn schon bekannt...
Mal schauen was passiert? Spannend!
Das nennt man Bereicherung, noch kurz vor der Übernahme, denn spätestens nach Übernahme können die diesbezüglich nichts mehr unternehmen...
ca. 3,3 Mio zusätzliche Aktien beinhaltet die Aktion!
Musste man die auch Registrieren lassen?
Da bin ich gespannt.
Wo kann man eigentlich die Spendenquittung beantragen?
Sollte bedeuten die Kursprognosen zu halbieren!
Dann besteht noch die Frage ob durch die Umsetzung des RIGHTS PLAN zusätzliche Aktien entstehen, oder ob sie in den 50 Mio enthalten sind. Denke aber das sie mit den 50 Mio$ abgedeckt sind.
Das wird interessant!
Darf ich mich freuen, dass Zop sehr wahrscheinlich erfolgreich wird oder muss ich jetzt Angst haben am Ende dank der Verwässerung +/- 0 dar zu stehen :D?